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Pregnant women and young infants are at high risk 
of developing severe inﬂ uenza.1,2 Among infants, 
those younger than 6 months have the highest risk of 
developing complications associated with inﬂ uenza;3 
however, antiviral treatments and inﬂ uenza vaccines 
are not approved in this age group. Given that inﬂ uenza 
vaccines administered to pregnant women have 
shown a good safety proﬁ le4 and eﬃ  cacy to prevent 
inﬂ uenza in infants younger than 6 months,5,6 maternal 
immunisation seems to be an important strategy to 
protect both pregnant women and their infants. WHO 
targets seasonal inﬂ uenza vaccination of pregnant 
women as a high priority.7 Most high-income countries 
recommend maternal inﬂ uenza immunisation to reduce 
the burden of inﬂ uenza in the pregnant woman and her 
infant.8 However, additional data are needed to support 
decisions about introduction of inﬂ uenza vaccine in 
pregnant women in resource-limited settings. The Bill 
& Melinda Gates Foundation funded three large trials 
in South Africa, Mali, and Nepal, with the objective of 
increasing the evidence base for the eﬀ ect of maternal 
inﬂ uenza immunisation.9 
In The Lancet Infectious Diseases, Milagritos D Tapias 
and colleagues10 report results of the trial done in Mali—a 
poorly-resourced country with high infant and maternal 
mortality. This is the largest randomised controlled trial 
evaluating the eﬃ  cacy, safety, and immuno genicity of 
trivalent inactivated inﬂ uenza vaccine administered to 
third-trimester pregnant women to prevent inﬂ uenza 
in infants younger than 6 months. 4193 women were 
immunised: 2018 with tri valent inactivated inﬂ uenza 
vaccine and 2085 with conjugate quadrivalent meningo-
coccal vaccine. Vaccine eﬃ  cacy against ﬁ rst-episode 
laboratory conﬁ rmed inﬂ uenza in infants (the primary 
outcome) was 33·1% (95% CI 3·7–53·9) in infants born 
to women immunised at any time prepartum (intention-
to-treat analysis), and 37·3% (7·6–57·8) in those born 
to women vaccinated at least 14 days prepartum 
Brink and colleagues are to be congratulated on their 
initiative and results.4 3 years after implementation, 
85% of institutions were using all ﬁ ve principles of their 
“low hanging fruit” interventions. However, the role 
of education in this area is key. The recent ﬁ rst online 
global antibiotic stewardship course hosted by the 
British Society of Antimicrobial Chemotherapy already 
has more than 25 000 registered voters and more than 
9000 active participants. It is encouraging to note that 
this course is undertaken by a range of professionals 
involved in combating antimicrobial resistance, in 
keeping with a team approach outlined in the study by 
Brink and colleagues.4
As the sun sets on the antimicrobial era, to paraphrase 
Dylan Thomas, “let us not go gentle into that good 
night, but  rage, rage against the dying of the light”.8
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(per-protocol analysis). Among participating women, 
vaccine eﬃ  cacy was 70·3% (95% CI 42·2–85·8) overall, 
76·6% (28·4–94·3) in pregnant women, and 70·1% 
(28·0–89·1) in the post-partum period. There was no 
beneﬁ cial eﬀ ect of the trivalent inactivated inﬂ uenza 
vaccine on birthweight. The technical and logistical 
feasibility of implementation of a new maternal 
immunisation programme was also shown with a high 
rate of recruitment among eligible women.
Evidence of the eﬃ  cacy of maternal inﬂ uenza 
immunisation to prevent inﬂ uenza in infants in low-
income countries from this trial is convincing and 
in agreement with ﬁ ndings from the two previously 
reported randomised trials from Bangladesh 
(63% vaccine eﬃ  cacy, 95% CI 5–85)5 and South Africa 
(48·8%, 11·6–70·4).6
However, important questions follow. First, is the 
health impact of maternal inﬂ uenza immunisation 
(on pregnant women, fetuses, and neonates) and 
countries’ demands enough to justify support from 
international agencies (eg, GAVI, the Vaccine Alliance) 
and others? Maternal inﬂ uenza immunisation 
could avert around 45 deaths per 100 000 people 
vaccinated in GAVI-eligible countries—ie, about 
210 000 mother–infant deaths from 2015 to 2030 
with broad adoption across GAVI countries.11 However, 
these ﬁ gures are estimates, and more speciﬁ c data 
for inﬂ uenza burden in poor-income countries are 
needed to better estimate health impact and convince 
decision makers. Second, is maternal inﬂ uenza 
immunisation acceptable for pregnant women and 
health providers? In high-income countries, inﬂ uenza 
vaccine coverage is less than 50%, even during the 
2009 H1N1 pandemic.12,13 However, in resource-limited 
countries, routine administration of tetanus toxoid 
vaccine as an important part of antenatal care should 
facilitate both implementation and acceptability of 
inﬂ uenza vaccine from pregnant women and health 
workers. The third question is regarding the feasibility 
of seasonal vaccine supply, surveillance, and strain-
matching? Logistical challenges with supplying, 
stocking, and administration of seasonal vaccines 
should be overcome to achieve high coverage of 
maternal immunisation. Development of maternal 
immunisation platforms in low-income countries 
seems to be an appealing approach. 
The results of Tapia and colleagues’ large randomised 
trial are important because they show not only the 
eﬃ  cacy, but also the feasibility, of maternal seasonal 
inﬂ uenza immunisation on infant protection during the 
ﬁ rst months of life in Mali. Moreover, the investigators 
put forward several propositions to overcome the 
diﬃ  culties of seasonal inﬂ uenza vaccination in resource-
limited countries. Nevertheless, supplementary data for 
inﬂ uenza disease burden in low-income countries are 
urgently needed to support GAVI’s decision. 
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